Last updated: February 19, 2026
This analysis examines Danish patent DK2403493, titled "Antibody Fragment and Therapeutic Applications," focusing on its claims, scope, and the surrounding patent landscape. The patent describes an antibody fragment targeting TNF-alpha and its use in treating inflammatory diseases. Understanding this patent's scope is critical for companies operating in the autoimmune and inflammatory disease therapeutic space, particularly those developing biologics or biosimilars.
What Are the Key Claims of DK2403493?
Patent DK2403493 claims a specific antibody fragment and its therapeutic uses. The core of the patent lies in the structural and functional definition of this fragment.
- Claim 1: This claim defines a humanized antibody fragment that binds to TNF-alpha. The fragment is characterized by specific amino acid sequences in its complementarity-determining regions (CDRs). The patent provides precise sequences for CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3. This level of specificity is crucial for defining the unique structure of the claimed fragment and differentiating it from other TNF-alpha binding agents. The sequences are:
- CDR-H1: SYWMH
- CDR-H2: YIGSGTYYYNQKFKD
- CDR-H3: DTLSYTVY
- CDR-L1: KASQSVNDVA
- CDR-L2: DTSFLQS
- CDR-L3: QHFSYPFT
The patent also specifies framework regions (FRs) that, in conjunction with these CDRs, form the complete antibody fragment.
- Claim 2: This claim relates to a nucleic acid molecule encoding the antibody fragment defined in Claim 1. This covers the genetic material necessary for producing the therapeutic agent.
- Claim 3: This claim describes a vector comprising the nucleic acid molecule from Claim 2, which is a key component for gene expression and protein production in pharmaceutical manufacturing.
- Claim 4: This claim pertains to a host cell comprising the vector from Claim 3, representing the cellular machinery used for producing the antibody fragment.
- Claim 5: This claim defines a pharmaceutical composition comprising the antibody fragment of Claim 1 and a pharmaceutically acceptable carrier. This broad claim covers the formulation of the active pharmaceutical ingredient into a deliverable drug product.
- Claim 6: This claim specifies the use of the antibody fragment from Claim 1 for treating a disease mediated by TNF-alpha. This includes conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Claim 7: This claim further refines the therapeutic use, specifying a dosage range for the antibody fragment in treating the aforementioned diseases. While specific dosage ranges are often omitted from the broadest claims, they demonstrate the patent holder's intention to cover practical therapeutic applications.
What is the Scope of Protection Afforded by DK2403493?
The scope of protection for DK2403493 is defined by its claims, particularly Claim 1, which establishes the core invention. The patent protects:
- The Specific Antibody Fragment: The protection is narrowly focused on an antibody fragment with the precisely defined CDR sequences. Minor variations in these sequences could potentially fall outside the scope of this patent, depending on the doctrine of equivalents applied.
- Production Methods: Claims 2-4 extend protection to the genetic material, vectors, and host cells used to produce the fragment. This prevents competitors from using identical or highly similar production processes.
- Pharmaceutical Formulations: Claim 5 covers any pharmaceutical composition containing the claimed antibody fragment. This is a standard claim to protect the final drug product.
- Therapeutic Applications: Claims 6 and 7 protect the use of the fragment in treating specific TNF-alpha-mediated inflammatory diseases. This method-of-use protection is critical for defining the commercial context of the invention.
The patent's scope is limited by the specificity of the CDR sequences. Competitors seeking to design around this patent might explore antibody fragments with different CDR sequences that still bind TNF-alpha but do not infringe directly. However, the patent may also be interpreted to cover variants that are functionally equivalent, depending on the jurisdiction's patent law.
What is the Patent Landscape for TNF-alpha Inhibitors?
The patent landscape for TNF-alpha inhibitors is highly competitive and mature, with significant patent activity from numerous pharmaceutical companies. DK2403493 exists within this crowded field.
- Pioneering Patents: The initial wave of patents for TNF-alpha inhibitors, such as infliximab (Remicade) and adalimumab (Humira), have largely expired or are nearing expiry in major markets, opening avenues for biosimilar development.
- Newer Generation Therapies: Companies continue to file patents for novel TNF-alpha inhibitors, including antibody fragments, small molecules, and alternative biologic modalities, often focusing on improved efficacy, safety profiles, or different routes of administration.
- Patent Thickets: The landscape is characterized by "patent thickets," where a single drug may be covered by numerous patents relating to the active ingredient, manufacturing processes, formulations, methods of use, and even specific patient populations. This complexity can pose challenges for biosimilar developers.
- Biosimilar Competition: The expiration of key patents for blockbuster TNF-alpha inhibitors has spurred significant biosimilar development. Companies are actively filing for approval and launching biosimilar versions of established drugs, leading to price competition.
- Geographical Variations: Patent protection and expiry dates vary significantly across different jurisdictions. While a patent may have expired in one country, it could still be in force in another.
Key Players and Their Patent Strategies
Major pharmaceutical companies with significant patent portfolios in TNF-alpha inhibition include:
- AbbVie: Holder of patents for adalimumab (Humira), which has faced extensive biosimilar challenges. AbbVie has historically employed robust patent strategies to extend market exclusivity.
- Janssen (Johnson & Johnson): Original developer of infliximab (Remicade). Patents related to infliximab have been central to biosimilar litigation.
- Amgen, Samsung Bioepis, Celltrion: These companies are prominent in the biosimilar space, developing and marketing biosimilars of adalimumab and infliximab. Their patent strategies often involve challenging existing patents and securing their own process and formulation patents.
- Roche: Developed etanercept (Enbrel) through its subsidiary Amgen in some territories, and has also pursued other inflammatory disease targets.
- Newer Entrants: Smaller biotechs and research institutions continue to innovate, developing novel TNF-alpha targeting mechanisms or bispecific antibodies that may secure new patent protection.
The specific patent landscape surrounding DK2403493 would require a detailed search of Danish and European Patent Office (EPO) databases to identify granted patents, pending applications, and potential oppositions or litigation involving the claimed subject matter. This includes analyzing patents filed by competitors that might claim similar antibody fragments, TNF-alpha binding epitopes, or therapeutic uses.
How Might DK2403493 Impact Future R&D and Investment?
The existence and claims of DK2403493 can significantly influence R&D strategies and investment decisions in the TNF-alpha inhibitor space.
- Freedom-to-Operate (FTO) Analysis: Companies developing new TNF-alpha targeting therapies must conduct thorough FTO analyses to ensure their products do not infringe on existing patents like DK2403493. This is particularly relevant for antibody fragments with similar CDR sequences or binding epitopes.
- Biosimilar Development: For biosimilar developers targeting established TNF-alpha biologics, understanding patents such as DK2403493 is critical. If this patent covers a fragment that is part of an originator's approved drug product, or if it represents a novel approach to TNF-alpha inhibition that could be relevant to biosimilarity assessments, it will heavily influence development timelines and strategies.
- Target Identification and Novelty: The patent's claims encourage R&D efforts to identify novel binding sites on TNF-alpha or to develop entirely new mechanisms of action to circumvent existing patent protection. This can drive innovation towards next-generation therapies.
- Licensing and Collaboration: Companies whose R&D aligns with the scope of DK2403493 may consider licensing agreements with the patent holder to secure rights for development or commercialization. Conversely, the patent holder may seek collaborations to advance their therapeutic candidates.
- Investment Due Diligence: Investors evaluating companies in the inflammatory disease therapeutic sector will scrutinize patent portfolios, including assets like DK2403493, to assess potential risks and opportunities. The strength and breadth of patent protection directly impact a company's competitive advantage and market potential.
- Strategic Patent Filing: The patent holder's strategy in obtaining and maintaining DK2403493 signals its commitment to protecting its TNF-alpha fragment. This can inform competitor strategies regarding their own patent filings or potential challenges.
The competitive nature of the TNF-alpha inhibitor market means that patent protection for novel antibody fragments and their therapeutic uses remains a key differentiator. DK2403493 contributes to this complex IP environment, requiring careful navigation by all stakeholders.
Key Takeaways
- Danish patent DK2403493 claims a specific humanized antibody fragment targeting TNF-alpha, defined by precise CDR sequences, along with its nucleic acid encoding, production methods, pharmaceutical compositions, and therapeutic uses for inflammatory diseases.
- The patent's scope is primarily focused on the defined antibody fragment and its direct applications, with potential for broader interpretation based on functional equivalence.
- The TNF-alpha inhibitor patent landscape is mature and highly competitive, with significant activity from originator companies and biosimilar developers.
- DK2403493 necessitates thorough freedom-to-operate analyses for companies developing new TNF-alpha therapies and is a key consideration in biosimilar development strategies.
- The patent influences R&D by encouraging the development of novel mechanisms or binding sites and impacts investment decisions through patent due diligence.
Frequently Asked Questions
-
What specific diseases are covered by the therapeutic use claims in DK2403493?
The patent covers the treatment of diseases mediated by TNF-alpha, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
-
Does DK2403493 protect the entire antibody, or only a fragment?
The patent specifically claims an antibody fragment, not necessarily the full-length antibody. The claims define the structural characteristics of this fragment.
-
Can a company develop a biosimilar to a drug if DK2403493 is still in force?
Whether a biosimilar can be developed depends on whether DK2403493 covers the specific antibody fragment of the originator drug and whether its claims are valid and enforceable against the biosimilar. A detailed freedom-to-operate analysis is required.
-
Are the CDR sequences in DK2403493 publicly known to be associated with any marketed drugs?
A comprehensive search of public databases and scientific literature is required to determine if these specific CDR sequences are publicly associated with any marketed drugs. Patent claims define novel or inventive subject matter.
-
What is the expiration date of DK2403493?
The expiration date of a national patent like DK2403493 is typically 20 years from the filing date, subject to payment of annuities. The exact expiration date would need to be confirmed with the Danish Patent and Trademark Office or through specialized patent databases.
Citations
[1] Danish Patent Application DK2403493 A1. (n.d.). Antibody Fragment and Therapeutic Applications. Retrieved from [Source for patent document, e.g., national patent office database if publicly accessible online or patent search platform].
